![6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity](/docs/US/2021-09-07/US11111253B2/abs.jpg.600x600.jpg)
- 专利标题： 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
-
申请号： US16846089申请日： 2020-04-10
-
公开(公告)号： US11111253B2公开(公告)日： 2021-09-07
- 发明人: Donna M. Huryn , Peter Wipf , Jennifer Rubin Grandis , Matthew G. LaPorte , Paul A. Johnston , Mark E. Schurdak , Raffaele Colombo
- 申请人： UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- 申请人地址： US PA Pittsburgh
- 专利权人： UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- 当前专利权人： UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- 当前专利权人地址： US PA Pittsburgh
- 代理机构： Foley & Lardner LLP
- 主分类号： C07D513/04
- IPC分类号： C07D513/04 ; A61P35/00
![6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity](/abs-image/US/2021/09/07/US11111253B2/abs.jpg.150x150.jpg)
摘要：
Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.
公开/授权文献
信息查询
